Gina Mauro

Editorial Director, OncLive
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: 


Risk-Stratification Can Be Used to Prevent Overtreatment in Children, AYA Patients With Synovial Sarcoma

October 25th 2021

The use of risk stratification in children and adolescent and young adult patients with synovial sarcoma is an essential approach to appropriately tailoring local and systemic therapy and avoiding overtreatment.

Fixed-Dose Eniluracil Under Investigation in Advanced Refractory Gastrointestinal Cancers

September 23rd 2021

Fixed-dose eniluracil is being evaluated with escalating doses of capecitabine in patients with advanced, refractory gastrointestinal cancers, or in advanced GI cancers who are intolerant to fluoropyrimidine chemotherapy, as part of an open-label, phase 1b dose-escalation trial.

Challenges Identified With Low Clinical Trial Accrual for AYA Patients With Sarcoma

September 23rd 2021

R. Lor Randall, MD, discusses survey results in detail and what the sarcoma community can do to overcome clinical trial enrollment barriers for adolescent and young adult patients.

Adavosertib Improves PFS in RAS-/TP53-Mutant Metastatic Colorectal Cancer

September 21st 2021

Adavosertib demonstrated a 65% reduction in the risk of disease progression or death compared with active monitoring in patients with TP53-/RAS-mutant metastatic colorectal cancer following first-line chemotherapy.

Adjuvant Atezolizumab Shows Improvement in DFS, Time to Relapse in PD-L1+ Stage II-IIIA NSCLC Subgroups

September 20th 2021

Adjuvant treatment with atezolizumab led to an improvement in disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of PD-L1–positive patients with stage II to IIIA NSCLC, according to exploratory findings from the phase 3 IMpower010 trial.

TG-1701 Monotherapy or Plus Ublituximab/Umbralisib Shows Encouraging Results in Relapsed/Refractory CLL

September 20th 2021

TG-1701, a covalently bound BTK inhibitor, used as monotherapy or in combination with umbralisib and ublituximab, demonstrated promising activity and a manageable safety profile in patients with chronic lymphocytic leukemia.

Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer, But Nivolumab/Ipilimumab Arm Misses Mark

September 19th 2021

The frontline combination of nivolumab and chemotherapy upheld its improvement in progression-free and overall survival vs chemotherapy alone with longer follow-up of patients with advanced gastric, gastroesophageal junction, or esophageal cancer, according to data from the phase 3 CheckMate-649 trial.

cfDNA-Based MRD Assessment Is Feasible, Yields Highly Concordant Results in Relapsed/Refractory CLL

September 18th 2021

The use of a cell-free DNA–based minimal residual disease assay demonstrated feasibility and highly concordant results compared with 4-color flow cytometry and improved MRD detection in patients with chronic lymphocytic leukemia who were treated with time-limited venetoclax, acalabrutinib, and obinutuzumab.

Trastuzumab Deruxtecan Impresses With Clinical Activity in HER2-Mutant NSCLC

September 18th 2021

Fam-trastuzumab deruxtecan-nxki showcased robust and durable antitumor activity in previously treated patients with HER2-mutant non–small cell lung cancer.

Trastuzumab Deruxtecan Elicits Encouraging Activity in Western Patients With HER2+ Gastric/GEJ Cancer

September 17th 2021

Fam-trastuzumab deruxtecan-nxki as a second-line treatment elicited a 38% confirmed objective response rate in Western patients with HER2-positive gastric/gastroesophageal junction cancer.

Neoadjuvant Carboplatin Plus Paclitaxel, Without Veliparib, Improves pCR, EFS in TNBC

September 17th 2021

The addition of carboplatin to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide significantly improved pathological complete response rates and event-free survival in patients with treatment-naïve triple-negative breast cancer.

ESMO 2021: Oncology Experts Share Game-Changing Data in Breast Cancer, Gynecologic Malignancies

September 16th 2021

The 2021 ESMO Congress, held as a virtual format for the second consecutive year, is fast approaching and isn’t holding back in terms of pivotal data across malignancies, especially in breast cancer and gynecologic cancers.

Adjuvant Pembrolizumab Continues to Uphold DFS Benefit Across RCC Subgroups

September 14th 2021

Pembrolizumab as an adjuvant therapy compared with placebo continued to showcase an impressive disease-free survival benefit in patients with clear cell renal cell carcinoma following nephrectomy, with improvement observed across subgroups.

MSI-H/dMMR Prostate Cancer Linked With Response to Checkpoint Blockade

September 11th 2021

Patients with microsatellite instability–high or mismatch repair–deficient prostate cancer may be more likely to respond to treatment with checkpoint inhibitors compared with those who have high tumor mutational burden.

Durvalumab/Vicineum Combo Shows Early Safety, Activity in High-Grade NMIBC

September 11th 2021

The combination of durvalumab and Vicineum was found to be well tolerated and to elicit complete responses in patients with Bacillus-Calmette Guérin–unresponsive non–muscle invasive bladder cancer.

Talquetamab Continues to Impress in Relapsed/Refractory Multiple Myeloma

September 10th 2021

Talquetamab, an off-the-shelf T-cell redirecting, GP3C5D-targeting agent, has continued to show promising clinical activity in patients with relapsed/refractory multiple myeloma, especially when given at the recommended phase 2 dose of 405 µg/kg weekly in subcutaneous formulation.

Pirtobrutinib Shows Impressive Efficacy in Previously Treated CLL/SLL

September 9th 2021

Pirtobrutinib, showcased promising efficacy signals across dose levels in previously treated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Frontline Durvalumab/Chemo, With or Without Tremelimumab, Improves PFS in Advanced NSCLC

September 9th 2021

The first-line combination of durvalumab and chemotherapy, with or without tremelimumab, led to a statistically significant improvement in progression-free survival compared with chemotherapy alone in patients with metastatic non–small cell lung cancer, according to data from the phase 3 POSEIDON trial.

Mobocertinib Elicits Efficacy in Advanced EGFR Exon 20 Insertion+ NSCLC Regardless of Prior Immunotherapy

September 9th 2021

Mobocertinib demonstrated clinical activity in previously platinum-treated patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer whether or not they received a prior PD-1/PD-L1 inhibitor.

Pembrolizumab Approved in China for Frontline Advanced Esophageal or GEJ Cancer

September 7th 2021

The National Medical Products Administration in China has approved pembrolizumab for use in combination with platinum- and fluoropyrimidine-based chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic esophageal carcinoma or gastroesophageal junction cancer.